Welcome to our dedicated page for Apellis Pharmace news (Ticker: APLS), a resource for investors and traders seeking the latest updates and insights on Apellis Pharmace stock.
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) generates frequent news as a commercial-stage biopharmaceutical company focused on C3 complement science. Its updates often center on the performance and expansion of its approved C3-targeting medicines, SYFOVRE for geographic atrophy (GA) secondary to age-related macular degeneration and EMPAVELI/Aspaveli for complement-mediated rare diseases such as C3 glomerulopathy (C3G), primary IC-MPGN, and paroxysmal nocturnal hemoglobinuria (PNH).
Investors following APLS news can expect regular disclosures on commercial execution, including U.S. net product revenues, patient start forms, market share in GA, and payer coverage trends in C3G and primary IC-MPGN. Apellis also issues news on long-term clinical data, such as five-year GALE extension results for SYFOVRE and one-year VALIANT data for EMPAVELI, which highlight durability of treatment effect and safety profiles.
Another major category of Apellis news involves clinical and regulatory milestones. Releases cover Phase 2 and Phase 3 trial progress, pivotal trial initiations in new nephrology indications like focal segmental glomerulosclerosis and delayed graft function, regulatory approvals, and opinion timelines from agencies such as the U.S. Food and Drug Administration and the European Medicines Agency. The company also announces publication of key data in peer-reviewed journals, including The New England Journal of Medicine.
Corporate and financial communications are a further news stream, including quarterly financial results, cash and cash equivalents updates, royalty and collaboration agreements with partners such as Sobi, and participation in major healthcare and investor conferences. For readers tracking APLS, this news page provides a centralized view of Apellis’ commercial performance, pipeline evolution, regulatory events, and strategic transactions related to its complement-based therapies.
Apellis Pharmaceuticals (Nasdaq: APLS) announced its participation in two key investor conferences this November. The company will present at the Stifel 2020 Virtual Healthcare Conference on November 18 at 10:00 a.m. ET and at the Jefferies Virtual London Healthcare Conference on November 19 at 6:45 a.m. ET. CEO Cedric Francois will partake in a fireside chat and a podium presentation, respectively. Both events will be webcast live and available for replay for 90 days. Apellis focuses on developing innovative therapies for diseases involving the complement cascade.
Apellis Pharmaceuticals (Nasdaq: APLS) announced that eight abstracts highlighting the efficacy of pegcetacoplan for treating paroxysmal nocturnal hemoglobinuria (PNH) have been accepted for the virtual American Society of Hematology Annual Meeting from December 5-8, 2020. New analyses from the Phase 3 PEGASUS study show superior treatment response and quality-of-life improvements with pegcetacoplan compared to eculizumab. The matching-adjusted indirect comparison indicated notable enhancements in clinical outcomes when compared to ravulizumab, demonstrating pegcetacoplan's potential to redefine PNH care standards.
Apellis Pharmaceuticals announces a collaboration with Sobi for the co-development and ex-U.S. commercialization of systemic pegcetacoplan, potentially worth $1.25 billion. The EMA validated the marketing authorization application for pegcetacoplan in PNH. Key trial results include a 52% reduction in lesion growth in geographic atrophy patients and a 73.3% reduction in proteinuria in C3G patients. As of September 30, 2020, Apellis has $728.2 million in cash, supporting operations through 2022 despite a net loss of $135.7 million in Q3 2020.
Apellis Pharmaceuticals and Sobi have entered a strategic collaboration for the global co-development and exclusive ex-U.S. commercialization of systemic pegcetacoplan, a targeted C3 therapy. Apellis retains U.S. rights and global rights for ophthalmological pegcetacoplan. Sobi will pay an upfront fee of $250 million, with up to $915 million in milestones and royalties. The partnership aims to advance systemic pegcetacoplan in five registrational programs, targeting diseases in hematology, nephrology, and neurology, with pivotal studies slated to begin in 2021.
Apellis Pharmaceuticals (APLS) has released 18-month data from the Phase 1b APL2-103 study, demonstrating that intravitreal pegcetacoplan effectively slows the growth of geographic atrophy (GA) lesions. The post hoc analysis of seven patients exhibited a 52% reduction in lesion growth in the treated eye compared to the untreated eye. With no reported inflammation and only one case of new-onset exudation, the results indicate the safety of pegcetacoplan. Top-line data from the ongoing Phase 3 DERBY and OAKS studies are expected in Q3 2021.
Apellis Pharmaceuticals (APLS) announced results from a 41-patient observational study showing that elevated systemic levels of C3a correlate with COVID-19 severity. In a Phase 1/2 interventional study, initial safety results from six patients indicate APL-9, a targeted C3 therapy, may improve outcomes in severe cases. Key findings include that 97.5% of patients had significantly high C3a levels, averaging 3.7 times the upper limit of normal. An independent committee recommended continuing the investigation of APL-9, which is currently enrolling 60 more patients.
Apellis Pharmaceuticals (Nasdaq: APLS) announced positive results from the Phase 2 DISCOVERY study on pegcetacoplan for C3 glomerulopathy (C3G). Patients exhibited a mean reduction of over 65% in proteinuria after 48 weeks, a key indicator of kidney damage. The study included eight C3G patients, where one showed a 73.3% decrease in proteinuria, alongside improvements in serum albumin and renal function. No severe adverse events were recorded, demonstrating the treatment's potential for this rare disease without approved therapies.
Apellis Pharmaceuticals has granted equity awards to four new employees as an inducement to join the company. The awards, totaling options for 25,962 shares and 4,275 restricted stock units (RSUs), were approved under the 2020 Inducement Stock Incentive Plan. The options have an exercise price of $31.77, equal to the stock's closing price on the grant date, October 1, 2020. Vesting for options occurs yearly after the first year, while RSUs vest at 25% annually. This initiative aims to enhance workforce engagement and retention.
Apellis Pharmaceuticals (APLS) announced the initiation of registrational programs for pegcetacoplan in treating C3 glomerulopathy (C3G) and amyotrophic lateral sclerosis (ALS). Both conditions currently lack approved treatments. The Phase 2 NOBLE study for C3G will dose its first patient by year-end, with data from the Phase 2 DISCOVERY trial supporting its advancement. Additionally, a potentially registrational Phase 2 study in ALS will enroll about 200 patients globally, with the first patient expected to be dosed by year-end 2020.
Apellis Pharmaceuticals reported a significant finding from the post hoc analysis of the Phase 2 FILLY study, demonstrating that monthly treatment with pegcetacoplan resulted in a 39% reduction in the progression rate from nascent Geographic Atrophy (GA) to GA compared to sham treatment. The analysis included 42 pegcetacoplan-treated and 69 sham-treated patients and the results were presented at the 2020 EURETINA conference. These findings suggest a potential benefit for earlier intervention in GA management, particularly since there are currently no approved treatments for this condition affecting millions globally.